SCHEMBL9528397

SCHEMBL9528397

COc1c(O)c2ccccc2oc1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.62
CA12 O43570 2/20 0.60
CA9 Q16790 2/20 0.60
MAOB P27338 1/20 0.60
MAPT P10636 4/20 0.57
ALDH1A1 P00352 4/20 0.57
TP53 P04637 3/20 0.57
MEN1 O00255 2/20 0.57
CYP3A4 P08684 2/20 0.57
KMT2A Q03164 2/20 0.57
PKM P14618 1/20 0.57
HPGD P15428 1/20 0.57
ALOX12 P18054 1/20 0.57
RECQL P46063 1/20 0.57
BLM P54132 1/20 0.57
HSD17B10 Q99714 1/20 0.57
NQO1 P15559 3/20 0.56
VKORC1 Q9BQB6 1/20 0.56
ABCB11 O95342 1/20 0.56
LMNA P02545 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29854772 0.84 CA12 (0.66) KDM4ECA12CA9MAOBMAPT
SCHEMBL831768 0.84 CA12 (0.66) KDM4ECA12CA9MAOBMAPT
SCHEMBL10719061 0.83 HSD17B10 (0.70) KDM4ECA12CA9MAOBALDH1A1
SCHEMBL2266790 0.81 CA12 (0.58) KDM4ECA12CA9MAOBMAPT
SCHEMBL10717699 0.80 KDM4E (0.54) KDM4ECA12CA9ALDH1A1TP53
SCHEMBL8496689 0.80 CSNK2A2 (0.53) KDM4ECA12CA9MAOBMAPT
SCHEMBL8486448 0.80 KDM4E (0.61) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL7346302 0.79 GAA (0.62) KDM4ECA12CA9MAPTALDH1A1
SCHEMBL8087605 0.79 NQO1 (0.69) KDM4ECA12CA9MAOBMAPT
SCHEMBL28761755 0.79 ALDH1A1 (0.56) KDM4ECA12CA9MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9616033-B2 Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactivities VIRGINIA COMMONWEALTH UNIVERSITY (US) 2017-04-11 US disclosed
US-20160051536-A1 COMPOSITIONS TO ALLEVIATE PRESYSTEMIC METABOLISM OF OPIOIDS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2016-02-25 US disclosed
EP-2983668-A1 COMPOSITIONS TO ALLEVIATE PRESYSTEMIC METABOLISM OF OPIOIDS Virginia Commonwealth University (US) 2016-02-17 EP disclosed
WO-2014168925-A1 COMPOSITIONS TO ALLEVIATE PRESYSTEMIC METABOLISM OF OPIOIDS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2014-10-16 WO disclosed
US-20140221426-A1 SELECTIVE METABOLIC APPROACH TO INCREASING ORAL BIOAVAILABILITY OF PHENYLEPHRINE AND OTHER PHENOLIC BIOACTIVITIES VIRGINIA COMMONWEALTH UNIVERSITY 2014-08-07 US disclosed
EP-2760441-A2 SELECTIVE METABOLIC APPROACH TO INCREASING ORAL BIOAVAILABILITY OF PHENYLEPHRINE AND OTHER PHENOLIC BIOACTIVES Virginia Commonwealth University (US) 2014-08-06 EP disclosed
WO-2013049365-A2 SELECTIVE METABOLIC APPROACH TO INCREASING ORAL BIOAVAILABILITY OF PHENYLEPHRINE AND OTHER PHENOLIC BIOACTIVES VIRGINIA COMMONWEALTH UNIVERSITY (US) 2013-04-04 WO disclosed
EP-0550493-A1 ANTHELMINTIC AND ANTICOCCIDAL 3-CARBAMOYL-4-HYDROXYCOUMARINS, METHOD OF USE AND COMPOSITIONS. UPJOHN CO (US) 1993-07-14 EP disclosed
WO-1992006083-A1 ANTHELMINTIC AND ANTICOCCIDAL 3-CARBAMOYL-4-HYDROXYCOUMARINS, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1992-04-16 WO disclosed